Israel-based Angioslide closed a $6.3 million Series C financing round led by TriVentures, a venture capital fund specializing in medical device technology investments, aimed at expanding its technology in the U.S.
Also participating in the round was return investor’s Viola Partners, Agate and XT Investments, according to the company.